Patients with PS or LC show persistent systemic inflammation 12 months after the acute COVID-19 episode, but CCL3 and CCL19 are specifically associated with PS, and the deterioration of DLCO in these patients, whereas LC patients present increased circulating levels of organ-damage markers. The gene discussed is CCL3; the disease is COVID-19.